Report: Medicare Negotiation Should Target Pricey Drugs With Chart: Medicare Spends Most of Its Rx Dollars on Small Share of Drugs

An April 19 analysis by the Kaiser Family Foundation (KFF) found that a small number of drugs accounted for the majority of spending in Medicare, and that drug pricing negotiation could lower overall spending in the program. Negotiating drug prices for Medicare has become a hot topic in health care policy circles, and it is one of the options on the table as Congress considers options to control drug costs (RDB 3/25/21, p. 1).

According to the report, the 250 top-selling drugs in Medicare Part D with one manufacturer and no generic or biosimilar competition accounted for 60% of net total Part D spending, while the top 50 drugs covered under Medicare Part B accounted for 80% of total Part B drug spending (see infographic, p. 6).

© 2021 MMIT

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Drug_Benefits_Life_Sciences.jpg
November 23

Will ‘Build Back Better’ Spell Disaster for Pharma Innovation?

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-health-plan-weekly-Wall-Street-Isnt-Sweating-Cignas-Third-Quarter-MLR-Miss.jpg
November 23

Big Three PBMs’ 3Q Results Make Up for Insurer Disappointments

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_442155384.jpg
November 23

SCAN Health Opts to Invest in Medication Adherence Tool

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today